Introduction In malaria‐stricken regions, malaria continues to be one of the primary causes
of mortality for children. The number of malaria‐related fatalities has drastically decreased …

Malaria remains the most serious infectious disease and is one of the leading causes of
death among children in malaria endemic areas. The development of malaria vaccines has …

Introduction Mass malaria vaccination, rather than vaccinating only children below age 5,
has been proven to have the potential to reduce morbidity and mortality among those …

Background Following a 30-year development process, RTS, S/AS01E (GSK, Belgium) is
the first malaria vaccine to reach Phase IV assessments. The World Health Organization …

Background The Malaria Vaccine Implementation Program, coordinated by the World Health
Organization, intended to initiate the roll-out of the RTS, S/AS01 malaria vaccine in 3 sub …

The malaria vaccine candidate, RTS, S/AS01E, showed promising protective efficacy in a
trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the …

The first clinical Phase III trial evaluating a malaria vaccine was completed in December
2013 at 11 sites from seven sub-Saharan African countries. This systematic review assesses …

Abstract Background GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative
are working in partnership to develop a malaria vaccine to protect infants and children living …

Background The development of a malaria vaccine remains a public health priority for sub‐
Saharan Africa. RTS, S/AS02A candidate malaria vaccine has been shown to be safe and …

Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …